Lumos Diagnostics Holdings Ltd.ASX: LDX

U.S FDA Deprioritises EUA Application for CoviDx

· Issued by Lumos Diagnostics Holdings Ltd.

Filed with ASX · · 2 pages · English

SARASOTA, Fla. (22 September 2021)– Lumos Diagnostics(ASX:LDX), a leader in rapid point-of-care (POC) diagnostic technologies, has received correspondence from the U.S. Food and Drug Administration (FDA) indicating that the FDA has deprioritised Lumos’ request for Emergency Use Authorization (EUA) for the CoviDx™ SARS-CoV-2 Rapid Antigen Test (CoviDx™) and has ceased review of the EUA at this time

Lumos Diagnostics Holdings Ltd. on 6ix

Earlier from Lumos Diagnostics

Later from Lumos Diagnostics

All Lumos Diagnostics news releases